Current version snapshot

Not FDA-approved↗Safety records↗

Current · version 4: TB-500↗↗

Related names recorded in this version: N-terminal acetylated 17-23 fragment of thymosin beta-4↗↗

A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule. 278

What this version reported

FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

TB-500 is a synthetic seven-amino-acid peptide copied from one segment of the natural protein thymosin beta-4. It is not the same substance as thymosin beta-4, and the research on it comes from animal and laboratory studies.2 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved product containing it in any of the countries it checked.2 FDA found no studies of TB-500 in people. One registered trial was listed as recruiting in its March 2026 registry record, with no results posted.2,5 FDA staff recommended against adding TB-500 to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.2,7,8

At a glance

What it is
A synthetic, N-acetylated peptide matching amino acids 17 to 23 (LKKTETQ) of thymosin beta-4. FDA’s substance registry notes that its identity record does not imply regulatory review or approval.1,2
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,7,8
Human evidence
None found by FDA. One Phase 1/2 trial was listed as recruiting in its March 2026 registry record, with no results posted.2,5
Sport status
FDA’s briefing notes that TB-500 is on the World Anti-Doping Agency’s prohibited list under section S2.3, as FDA checked in February 2024.2
Evidence strength
Animal and lab studies only

What is TB-500?

TB-500 is a synthetic peptide of seven amino acids, LKKTETQ, with an acetyl group added at one end. The sequence matches amino acids 17 to 23 of thymosin beta-4, a 43-amino-acid protein found throughout the body.2

Websites often call TB-500 a synthetic version of thymosin beta-4, but FDA’s briefing states that they are not the same substance.2

TB-500 appears to have first been made in 2003. A veterinary preparation appeared in 2011 and was marketed to boost performance in horse and greyhound racing. FDA could not identify any pharmacy that compounds it, and no outsourcing facility had reported compounding it.2

How is TB-500 thought to work?

TB-500 contains the segment of thymosin beta-4 that binds actin, a protein that helps cells keep their shape and move. Researchers have proposed that this could help wound healing, but that has not been shown for TB-500.2

In a laboratory study, TB-500 itself did not speed the closing of scratch wounds in cultured cells. FDA states that it remains unknown whether TB-500 has wound-healing effects in living animals.2

Studies in horses and laboratory models show that TB-500 is broken down into several smaller fragments. Except for one, the effects of those fragments are unknown.2

What do human studies show?

There are none in FDA’s review. FDA evaluated TB-500 for wound healing and found no clinical studies or other human exposure data for it by any route.2

The three references submitted to FDA in support of TB-500 were studies of thymosin beta-4 in animals or the laboratory.2

FDA’s adverse-event search through March 2025 found no reports. A search of FDA’s food and supplement complaint system found two cases about a blend of TB-500 and BPC-157, without safety assessments.2

One Phase 1/2 trial in atherosclerotic cardiovascular disease and endothelial dysfunction was listed as recruiting in its March 23, 2026 registry record, with no results posted.5

What the evidence base contains

  • Animal or laboratory research A laboratory study in which TB-500 did not speed the closing of scratch wounds in cultured cells, while one of its breakdown products had a small effect.2
  • Animal or laboratory research A study in aged mice in which a related fragment without TB-500’s acetyl group improved wound closure. FDA says those results cannot be directly carried over to TB-500.2
  • Animal or laboratory research Studies in horses and laboratory models showing that TB-500 reaches the bloodstream and is broken down into smaller fragments.2
  • Registered trial without results A Phase 1/2 trial of TB-500 in atherosclerotic cardiovascular disease and endothelial dysfunction, listed as recruiting in its March 23, 2026 registry record, with no results posted.5

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is TB-500 FDA-approved?

No. FDA’s May 2026 evaluation states that neither TB-500 free base nor TB-500 acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.2

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.7

FDA staff evaluated both forms of TB-500 for that list for wound healing and recommended against adding either. They cited poor chemical characterization, no human data on safety or effectiveness, a possible risk of immune reactions, and existing FDA-approved wound treatments.2

FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.4

HHS’s policy document states that TB-500 was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.4,8

FDA’s Pharmacy Compounding Advisory Committee discussed TB-500 on July 23, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.2,3,8

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.7,8

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For TB-500, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.8

HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates supply the quality test results FDA staff found missing, that use is now documented, and that FDA staff’s safety concerns are inferred rather than observed, pointing to human safety data on the parent protein. FDA staff had found no human data on TB-500 itself.2,8

The policy does not make TB-500 an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.7,8

Timeline

  1. TB-500 appears to have first been made from the thymosin beta-4 sequence, according to the literature FDA reviewed.2
  2. A veterinary preparation of TB-500 appears and is marketed to boost performance in horse and greyhound racing.2
  3. TB-500 is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.8
  4. A ClinicalTrials.gov record version lists a Phase 1/2 TB-500 trial as recruiting.5
  5. A Federal Register notice announces the July advisory-committee meeting that will discuss TB-500 and opens a public comment docket.6
  6. TB-500 leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.4,8
  7. FDA staff date their evaluation recommending that TB-500 not be added to the 503A bulks list.2
  8. FDA’s Pharmacy Compounding Advisory Committee discusses TB-500.3
  9. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists TB-500 among six peptide substances used in compounding.7,8

What is still unknown?

Whether TB-500 has any benefit in people, or even promotes wound healing in animals: FDA found no human studies and no animal wound-healing studies of TB-500 itself.2

Its safety in people, including whether it can trigger immune reactions, and what its breakdown products do.2

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that TB-500 and thymosin beta-4 are often confused.2

Whether FDA’s rulemaking will add TB-500 to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.2,7,8

Sources for this version

  1. 1
    TB-500 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  2. 2
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    ClinicalTrials.gov record NCT07487363 · retained source version 2026-03-23:eb4b60623fcf6b4ae3df79179184b1b2b5a5502180a2163da52ebf8c09c10e1e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  6. 6
    Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026